Kazda S, Garthoff B, Knorr A
Fed Proc. 1983 Feb;42(2):196-200.
Nitrendipine is a calcium antagonistic 1,4-dihydropyridine derivative with a pronounced antihypertensive activity in animal experiment. Similar to other calcium entry blockers, nitrendipine decreases blood pressure by lowering the elevated peripheral vascular resistance. However, its long-term effect differs from that of vasodilators such as hydralazine and minoxidil. In contrast to vasodilators, nitrendipine reduces heart hypertrophy in various forms of experimental hypertension in rats. Nitrendipine is highly effective in normalizing blood pressure, reducing heart hypertrophy, and preventing mortality in salt-related hypertension (two-kidney renal hypertension, salt-induced hypertension in Dahl rats), which are rather refractory to the effect of vasodilators. Nitrendipine reduces renovascular resistance in spontaneously hypertensive rats but has no effect on that of normotensive rats. In conscious renal hypertensive dogs, nitrendipine decreases blood pressure more than does hydralazine. The reflex tachycardia is more pronounced after hydralazine than after nitrendipine; blood pressure decrease is greater and the duration of the effect is longer than that of nifedipine. Nitrendipine is thus predicted as an effective drug for antihypertensive monotherapy.
尼群地平是一种钙拮抗型1,4 - 二氢吡啶衍生物，在动物实验中具有显著的降压活性。与其他钙通道阻滞剂相似，尼群地平通过降低升高的外周血管阻力来降低血压。然而，其长期作用与肼屈嗪和米诺地尔等血管扩张剂不同。与血管扩张剂相反，尼群地平可减轻大鼠各种形式实验性高血压中的心脏肥大。尼群地平在使血压正常化、减轻心脏肥大以及预防盐相关性高血压（双肾肾性高血压、Dahl大鼠盐诱导性高血压）的死亡率方面非常有效，而这些高血压对血管扩张剂的作用相当难治。尼群地平可降低自发性高血压大鼠的肾血管阻力，但对正常血压大鼠的肾血管阻力无影响。在清醒的肾性高血压犬中，尼群地平降低血压的作用比肼屈嗪更强。肼屈嗪后的反射性心动过速比尼群地平后更明显；血压下降幅度更大，且作用持续时间比硝苯地平更长。因此，尼群地平被预测为一种有效的抗高血压单一疗法药物。
